<DOC>
	<DOCNO>NCT02625961</DOCNO>
	<brief_summary>In study , participant high risk non-muscle-invasive bladder cancer ( NMIBC ) unresponsive Bacillus Calmette Guerin ( BCG ) therapy consider ineligible refuse undergo radical cystectomy , receive pembrolizumab therapy . The primary study hypothesis treatment pembrolizumab result clinically meaningful response .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With High Risk Non-muscle Invasive Bladder Cancer ( MK-3475-057/KEYNOTE-057 )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologicallyconfirmed diagnosis high risk nonmuscleinvasive ( T1 , high grade Ta / carcinoma situ ) transitional cell carcinoma bladder ( mixed histology tumor allow transitional cell histology predominant histology ) Absence resectable disease least 2 cystoscopy /transurethral resection ( TURBT ) procedure ( residual CIS acceptable ) BCGunresponsive high risk nonmuscleinvasive bladder cancer treatment adequate BCG therapy Ineligible radical cystectomy refusal radical cystectomy Available tissue newly obtain core biopsy tumor lesion previously irradiated Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Adequate organ function Female participant childbearing potential negative urine serum pregnancy test must willing use adequate method contraception Male participant must willing use adequate method contraception Exclusion criterion : Muscleinvasive , locally advance nonresectable , metastatic urothelial carcinoma ( i.e. , T2 , T3 , T4 , / stage IV ) Concurrent extravesical ( i.e. , urethra , ureter , renal pelvis ) nonmuscle invasive transitional cell carcinoma urothelium Currently participate participate study investigational agent receive study therapy receive investigational device within 4 week prior first dose study treatment Received intervening intravesical chemotherapy immunotherapy time recent cystoscopy / TURBT start study treatment Received prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior start study treatment recover adverse event due previously administer agent Known additional malignancy progress require active treatment except basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . A history prostate cancer treat definitive intent ( surgically radiation therapy ) acceptable Active autoimmune disease require systemic treatment past 2 year Evidence interstitial lung disease active noninfectious pneumonitis Active infection require systemic therapy Pregnant breastfeeding , expect conceive within project duration trial 120 day last dose study treatment Prior therapy antiprogrammed cell death 1 ( PD1 ) , antiPDligand 2 ( L2 ) agent , agent direct another coinhibitory Tcell receptor Known human immunodeficiency virus ( HIV ) Known active Hepatitis B C infection Received live virus vaccine within 30 day plan start study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PD-1</keyword>
</DOC>